Login to Your Account

Tumblers fall into place as BMS buys Padlock; enzymatic 'aha' moment keys up $600M deal

By Randy Osborne
Staff Writer

Wednesday, March 23, 2016

The study of arginine residue on proteins at Scripps Research Institute – a "pretty arcane" and "obscure" research area – that led to the forming of Padlock Therapeutics Inc. laid the foundation for Bristol-Myers Squibb Co.'s (BMS) $600 million buyout, Padlock CEO Michael Gilman told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription